Switch to:
Also traded in: Australia, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GENE's Cash-to-Debt is ranked higher than
99% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NAS:GENE: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GENE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.85  Med: 38.8 Max: No Debt
Current: No Debt
0.85
No Debt
Equity-to-Asset 0.86
NAS:GENE's Equity-to-Asset is ranked higher than
87% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NAS:GENE: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:GENE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.84 Max: 0.93
Current: 0.86
0.09
0.93
Piotroski F-Score: 2
Altman Z-Score: -6.26
Beneish M-Score: -3.53
WACC vs ROIC
15.36%
2311.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3007.69
NAS:GENE's Operating Margin % is ranked lower than
96% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NAS:GENE: -3007.69 )
Ranked among companies with meaningful Operating Margin % only.
NAS:GENE' s Operating Margin % Range Over the Past 10 Years
Min: -3007.69  Med: -116.21 Max: 6.75
Current: -3007.69
-3007.69
6.75
Net Margin % -3089.47
NAS:GENE's Net Margin % is ranked lower than
97% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. NAS:GENE: -3089.47 )
Ranked among companies with meaningful Net Margin % only.
NAS:GENE' s Net Margin % Range Over the Past 10 Years
Min: -3089.47  Med: -110.94 Max: 4.93
Current: -3089.47
-3089.47
4.93
ROE % -70.18
NAS:GENE's ROE % is ranked lower than
76% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. NAS:GENE: -70.18 )
Ranked among companies with meaningful ROE % only.
NAS:GENE' s ROE % Range Over the Past 10 Years
Min: -271.23  Med: -64.84 Max: 14.99
Current: -70.18
-271.23
14.99
ROA % -61.66
NAS:GENE's ROA % is ranked lower than
77% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. NAS:GENE: -61.66 )
Ranked among companies with meaningful ROA % only.
NAS:GENE' s ROA % Range Over the Past 10 Years
Min: -134.56  Med: -56.97 Max: 10.58
Current: -61.66
-134.56
10.58
ROC (Joel Greenblatt) % -1879.06
NAS:GENE's ROC (Joel Greenblatt) % is ranked lower than
89% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. NAS:GENE: -1879.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:GENE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2298.65  Med: -1145.3 Max: 65.76
Current: -1879.06
-2298.65
65.76
3-Year Revenue Growth Rate -100.00
NAS:GENE's 3-Year Revenue Growth Rate is ranked lower than
98% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:GENE: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:GENE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.6 Max: 39.5
Current: -100
0
39.5
3-Year EBITDA Growth Rate 37.00
NAS:GENE's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:GENE: 37.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GENE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -26 Max: 37
Current: 37
0
37
3-Year EPS without NRI Growth Rate 39.40
NAS:GENE's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:GENE: 39.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GENE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13 Max: 39.4
Current: 39.4
0
39.4
GuruFocus has detected 9 Warning Signs with Genetic Technologies Ltd NAS:GENE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GENE's 30-Y Financials

Financials (Next Earnings Date: 2018-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

GENE Guru Trades in Q3 2017

Jim Simons 989,280 sh (+5.00%)
» More
Q4 2017

GENE Guru Trades in Q4 2017

Jim Simons 984,580 sh (-0.48%)
» More
Q1 2018

GENE Guru Trades in Q1 2018

Jim Simons 982,980 sh (-0.16%)
» More
Q2 2018

GENE Guru Trades in Q2 2018

Jim Simons 841,926 sh (-14.35%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414    SIC: 2836
Compare:TSXV:SQD, OSL:NATTO, ROCO:4117, XCNQ:IME, TSXV:CVM, XCNQ:CHX, ROCO:4160, NGM:PRLD MTF, ASX:DVL, TSXV:MDX, ROCO:6645, NAS:IDXG, LSE:PRM, NAS:CODX, NAS:TROV, XKRX:214610, XPAR:ALTER, LSE:CRON, ROCO:6661, LSE:NIPT » details
Traded in other countries:GTG.Australia, GNTLF.USA,
Headquarter Location:Australia
Genetic Technologies Ltd is a molecular diagnostics company. It offers predictive testing and assessment tools to help physicians manage women's health.

Genetic Technologies Ltd is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and United States.

Ratios

vs
industry
vs
history
PB Ratio 3.27
GENE's PB Ratio is ranked higher than
62% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. GENE: 3.27 )
Ranked among companies with meaningful PB Ratio only.
GENE' s PB Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.14 Max: 23.33
Current: 3.27
0.7
23.33
EV-to-Revenue 56.03
GENE's EV-to-Revenue is ranked lower than
94% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. GENE: 56.03 )
Ranked among companies with meaningful EV-to-Revenue only.
GENE' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.8  Med: 1.6 Max: 12.2
Current: 56.03
-3.8
12.2
Current Ratio 6.95
GENE's Current Ratio is ranked higher than
85% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. GENE: 6.95 )
Ranked among companies with meaningful Current Ratio only.
GENE' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 4.29 Max: 13.76
Current: 6.95
1.08
13.76
Quick Ratio 6.95
GENE's Quick Ratio is ranked higher than
86% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. GENE: 6.95 )
Ranked among companies with meaningful Quick Ratio only.
GENE' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.17 Max: 13.76
Current: 6.95
1.04
13.76
Days Inventory 84.82
GENE's Days Inventory is ranked lower than
52% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. GENE: 84.82 )
Ranked among companies with meaningful Days Inventory only.
GENE' s Days Inventory Range Over the Past 10 Years
Min: 21.15  Med: 42.33 Max: 90.51
Current: 84.82
21.15
90.51
Days Sales Outstanding 297.02
GENE's Days Sales Outstanding is ranked lower than
100% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. GENE: 297.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
GENE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.06  Med: 47.97 Max: 297.02
Current: 297.02
13.06
297.02
Days Payable 415.06
GENE's Days Payable is ranked higher than
93% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. GENE: 415.06 )
Ranked among companies with meaningful Days Payable only.
GENE' s Days Payable Range Over the Past 10 Years
Min: 62.36  Med: 192.57 Max: 415.06
Current: 415.06
62.36
415.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -58.30
GENE's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. GENE: -58.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GENE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -7.5 Max: 0
Current: -58.3
-58.3
0

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -55.05
GENE's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. GENE: -55.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GENE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -272.1  Med: -35.1 Max: 112.6
Current: -55.05
-272.1
112.6

More Statistics

Revenue (TTM) (Mil) $0.19
EPS (TTM) $ -0.36
Beta4.16
Volatility86.09%
52-Week Range $0.70 - 2.05
Shares Outstanding (Mil)16.24 (ADR)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}